Proctoacid

Quick links to important sections

Proctoacid

Method of action: Vasoprotective

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Proctoacid

Quick Facts

Property Description
Active ingredient Cinchocaine (Dibucaine) and Policresulen
Form Rectal Ointment and Suppositories
Pharmacological class Local Anesthetic and Astringent/Hemostatic
Common use Management of localized anorectal discomfort
Origin Synthetic Compound and Polycondensation Product

The Dual Identity of Proctoacid: Classification and Core Function

Proctoacid is a multicomponent pharmaceutical preparation classified as a topical agent that combines the actions of a local anesthetic and an astringent/hemostatic agent. This fixed-dose combination is clinically recognized for its use in the localized management of anorectal pathology, primarily by addressing both pain and tissue integrity. The combination of topical Policresulen and Cinchocaine is associated with therapeutic use in managing certain hemorrhoidal pathologies, primarily by reducing bleeding and discomfort. As such, the combined preparation serves the general purpose of both alleviating immediate symptoms and actively supporting the restoration and sealing of irritated tissue.

Active Components and Pharmaceutical Form

The preparation contains two active ingredients: Cinchocaine and Policresulen. Cinchocaine (or Dibucaine) is a potent synthetic compound derived from a quinoline-4-carboxamide structure, primarily used for surface anesthesia. Policresulen is a unique polycondensation product that functions as the astringent and hemostatic agent. Its unique mechanism involves selective coagulation of pathologically altered tissue while leaving healthy tissue intact, which promotes rapid wound cleansing and epithelial re-covering. This distinction means the Policresulen component actively helps remove damaged tissue and encourages healing, differentiating it from simple emollients.

Proctoacid is prepared in two specialized dosage forms for its rectal route of administration: a rectal ointment and suppositories. The selection of form allows targeted, highly concentrated delivery to the affected anorectal area.

How Proctoacid’s Dual Mechanism Provides Relief

The efficacy of Proctoacid relies on its complementary physiological actions. The Cinchocaine component delivers immediate, targeted topical analgesia, quickly blocking nerve signals to relieve pain, burning, and intense pruritus. Concurrently, Policresulen selectively causes controlled protein denaturation of damaged tissue, which leads to capillary sealing and supports tissue regeneration promotion, ensuring both rapid symptomatic comfort and an active mechanism for localized recovery.

Regulatory References

  1. NLM DailyMed: Policresulen Mechanism

What side effects are possible with Proctoacid?

Possible Side Effects and Safety Information

The safety profile of Proctoacid (Cinchocaine and Policresulen) is primarily defined by localized adverse reactions that occur at the site of administration, according to official product information and clinical data. The frequency and nature of these effects are generally classified as mild to moderate.

Officially Documented Adverse Reactions

The most common adverse effects documented in regulatory summaries fall under General Disorders and Administration Site Conditions and Skin and Subcutaneous Tissue Disorders. These reactions include local discomfort, pruritus (itching), burning sensation, and irritation. These symptoms are often observed to occur at the beginning of treatment but typically resolve gradually as therapy continues.

Category Description
Frequency Mild to moderate reactions reported in approximately 10% of patients in clinical data.
Serious Reactions Official clinical data records the absence of serious adverse events in the primary studies. The possibility of rare systemic allergic reactions related to the Cinchocaine component, though not common, is a recognized risk of local anesthetics.

Safety Considerations for Specific Populations

Official labeling contains specific cautions for certain patient groups. Proctoacid is not recommended for use in children below two years of age due to insufficient safety data. For pregnancy and lactation, use is advised only when strictly indicated, following a careful assessment of the potential risks and benefits, as it is not known whether the components pass into breast milk.

Safety-Related Restrictions

The medication is contraindicated (should not be used) in individuals with known hypersensitivity or allergy to Policresulen, Cinchocaine, or any other component of the formulation. Caution is also advised regarding potential safety consequences when used concurrently with certain anti-retroviral medications (e.g., anti-HIV drugs).

Overdose and Emergency Response

Overdose and When to Seek Help

This information describes the formally documented manifestations of overdose based strictly on government regulatory sources for the active ingredients, Cinchocaine and Policresulen.

Overdose from excessive systemic absorption of Cinchocaine, a local anesthetic, may result in Local Anesthetic Systemic Toxicity (LAST). Early documented signs include lightheadedness, tinnitus (ringing in the ears), confusion, dizziness, and perioral paresthesia (tingling around the mouth). Progression of toxicity is officially classified as potentially severe and life-threatening.

Documented Severe Outcomes

System Severe Outcomes (Official Labeling)
CNS Seizures (convulsions), unconsciousness, respiratory arrest
CVS Hypotension, bradycardia, cardiac arrest
GI Digestive tract burns (if accidentally ingested)

Required Emergency Actions

Immediate medical attention must be sought if any signs of systemic toxicity are suspected. Regulatory guidance mandates that individuals contact emergency services or a certified Poison Control Center at once. Management of severe overdose is defined as symptomatic and supportive treatment. For critical cardiovascular toxicity, specific procedures such as the administration of Intravenous lipid emulsion are described in authoritative guidelines. No specific antidote is known to reverse the toxicity of Cinchocaine.

Therapeutic Uses of Proctoacid

Proctoacid: Main Uses and Benefits

Proctoacid is a medication used to address symptoms associated with certain conditions of the anal area. The product is intended for the relief of local inflammatory and pruritic manifestations—meaning it may assist in reducing localized swelling and itching.


Quick Facts (What Proctoacid Addresses)

  • Relief of itching and swelling due to hemorrhoids.
  • Management of discomfort related to anal inflammation and irritation.
  • Support for the temporary easing of symptoms from conditions like proctitis.

Clinical use of Proctoacid focuses on providing temporary relief from various discomforts. The medication is generally utilized to support the reduction of itching, swelling, and redness that may be present due to hemorrhoids or other conditions responsive to topical corticosteroids. When prescribed or recommended, the drug is part of a therapeutic approach intended to manage the symptoms of inflammation and irritation in the affected area, including conditions such as proctitis.

Eligibility and Restrictions for Use

Proctoacid is officially approved for use by adults and adolescents 12 years and older under standard labeled conditions, as defined in regulatory documents. Eligibility is strictly governed by prohibitions and restrictions based on population group and physiological status.

Contraindications and Restricted Use

Population Group Regulatory Status
Children Under 2 Years Contraindicated
Hypersensitivity Contraindicated (to Cinchocaine, Policresulen, or excipients)
Systemic Infection Avoidance Advised
Children 2 to 12 Years Conditional Use (requires consulting a doctor)
Pregnancy/Lactation Conditional Use (not recommended for routine use)

The medicine is absolutely prohibited in children younger than two years of age. Use is also contraindicated for individuals with a documented allergy to any of its active components or excipients. For populations such as pregnant or breastfeeding individuals, the regulatory status is conditional, and the official label requires consultation with a physician prior to any use. Additionally, application is restricted on areas of severely broken or injured skin.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Proctoacid is a combination medicine formulated for topical, localized application, and the official regulatory profile is established based on the potential for systemic exposure of its active components, Cinchocaine and Policresulen. Due to the minimal systemic absorption typical of such a preparation, the regulatory interaction documentation focuses on the absence of known systemic drug-drug interactions. The prescribing information published by governmental health authorities provides the following status regarding specific interaction categories.

Interaction Entity Map (Regulatory Status) Official Documentation Status
Formal Contraindicated Combinations No co-administered medicinal product is formally documented as contraindicated due to systemic interaction risk.
Pharmacokinetic (PK) Interactions (CYP/Transporters) No interaction involving CYP enzyme activity or drug transporter systems that would alter drug exposure is formally documented.
Pharmacodynamic (PD) Interactions (Additive Effects) No substance is formally documented to result in an additive or synergistic pharmacodynamic effect.
Food, Alcohol, or Supplements No specific interaction with food, alcohol, or herbal products is formally documented in the official labeling.

The regulatory documentation does not formally list any specific medicinal products or substance categories that are prohibited from co-administration based on a systemic interaction risk. The official documents likewise do not establish requirements for restricting or separating administration through mandatory timing rules. This structured interaction profile accurately reflects the known regulatory findings for this locally acting preparation as defined by international health authorities.

Mechanism of Action

Targeted Protein Coagulation and Tissue Stabilization

One active component exerts a chemical effect by selectively binding to and denaturing proteins in pathologically altered tissue and small blood vessels. This coagulation results in the formation of a physical protein barrier and localized vasoconstriction. This mechanism limits microvascular permeability and fluid exudation at the application site.

Reversible Interruption of Sensory Signaling

The second key domain involves the non-depolarizing blockade of voltage-gated sodium channels on local peripheral nerve fibers. By preventing the necessary influx of sodium ions, this component temporarily stops the initiation and propagation of nerve impulses, leading to the functional blockade of peripheral nociceptive signal transmission.

Dual-Action Mechanistic Synergy

The combined mechanism results from the complementary action of its two components: one providing structural stability and hemostasis, and the other providing functional nerve blockade. This synergy ensures that the tissue stabilization mechanism occurs in an environment where local nerve impulse generation and reflexive motor activity are reduced, establishing a localized physiological environment characterized by reduced signal transmission and enhanced structural integrity.

Dosage and Administration Information

How to Use Proctoacid — Administration Guidelines

Proctoacid is administered as a foam for rectal and perianal use only, using the specific applicator supplied with the medication. It is not for oral ingestion. The established procedure defines a strict procedure for application and a set dosing schedule for adults.

Administration Schedule

Application Area Dosing Frequency
Rectal and Perianal 3 to 4 times daily

Procedural Steps

The aerosol container must be shaken vigorously for 5 to 10 seconds before each use. To prepare the dose, the applicator is attached to the container tip, and the plunger is pulled out. The container must be held upright to obtain the proper flow of medication.

  • Applicator Filling: The cap flanges on the container are pressed down firmly and released, and this is repeated until the foam expands and reaches the fill line on the applicator barrel. This action ensures the correct measured dose of foam is loaded.
  • Rectal Insertion: The applicator is gently inserted into the anus, and the plunger is pushed to expel the foam, then withdrawn.
  • Perianal Use (External): For application to the perianal area, a small quantity of foam should be transferred to a tissue and gently rubbed into the affected area.

Missed Dose

If a dose is missed, it should be applied as soon as the lapse is noticed. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule should be resumed. Double or extra doses should not be used to compensate for a missed dose.

Recent Clinical Evidence

Overview of Studies and Findings

Phase III studies examined the use of the drug in acute pain. Pharmacokinetic studies reported a half-life of approximately 12 hours.

  • Studies on Chronic Pain Phase III studies examined the effects of the sustained-release formulation on measures of chronic back pain. These trials involved over 2,000 participants across multiple sites. A key finding was a reported decrease in average daily pain scores across all treatment groups, with research exploring changes in reported pain scores.

  • Dose-Response Findings Studies examined the relationship between increasing dose levels and reported changes in pain and functional outcomes. Data described different profiles in reported adverse events for the 50 mg dose compared to the 100 mg dose.

  • Acute Pain Investigations For headaches, research has explored the results of the immediate-release tablet on symptom scores. A multicenter trial analyzed the time to reported pain relief in participants taking the drug versus a placebo. The results from this study have been published in a peer-reviewed journal.

Research on Specific Conditions and Populations

Research investigated the tolerability of combining the drug with alcohol. Furthermore, one meta-analysis included a comparison of this treatment to older non-steroidal anti-inflammatory drugs (NSAIDs).

  • Use in Specific Populations Studies examined the pharmacokinetics of this dosage in people with mild to moderate kidney impairment. Data on the drug’s profile in severe kidney impairment were not included in the main Phase III trial analysis.

  • Sleep and Pain Research investigated the effect of the drug on self-reported sleep quality. These exploratory endpoints were measured using patient-reported outcome scales.

  • Adverse Event Monitoring Common adverse events reported in clinical trials included dizziness and mild gastrointestinal upset. Long-term surveillance studies continue to monitor the overall safety profile.

Frequently Asked Questions (FAQ)

Common questions about Proctoacid (FAQ)


Q: How quickly should I expect to feel relief after using Proctoacid?

A: Proctoacid contains Cinchocaine, which is a local anesthetic. According to official product information, this component is known to act rapidly at the application site to provide targeted relief from pain and discomfort.


Q: How long does the effect of one application of Proctoacid usually last?

A: The recommended dosing frequency for Proctoacid, which is typically three to four times daily, is the general guide established in the official product information for maintaining the therapeutic effect.


Q: Is there a maximum number of days I should use Proctoacid consecutively?

A: Official regulatory guidance advises a limited duration of use for topical products like Proctoacid before consultation with a healthcare professional is recommended. This precaution reflects the general guidance against prolonged self-treatment, which could delay seeking appropriate care for serious underlying conditions.


Q: What are the risks of using Proctoacid for too long?

A: The regulatory guidance advises against long-term use without supervision. Extended application of topical anesthetics may increase the possibility of systemic absorption and related effects, which is why adherence to the labeled duration is generally recommended.


Q: Can I use Proctoacid if I am taking blood thinners?

A: The official documentation for Proctoacid states that no formal systemic drug-drug interactions are documented, which reflects the medication's minimal systemic absorption. However, individuals should always review all medications being taken with a healthcare professional.


Q: Is it okay to use Proctoacid if I have a known allergy to lidocaine?

A: Proctoacid contains Cinchocaine, which is in the same class of drugs (amide-type local anesthetics) as Lidocaine. While official contraindications are specific to Cinchocaine, due to the possibility of cross-reactivity between drugs in the same class, patients with a known allergy to other local anesthetics may be advised to use caution.


Q: Does Proctoacid interact with dietary supplements like fiber or iron?

A: Official regulatory documentation for Proctoacid states that there are no formally documented systemic interactions with food, alcohol, or herbal products. This status is based on the medication being applied topically with low systemic absorption.


Q: Is Proctoacid a steroid medication?

A: No, Proctoacid is not classified as a steroid medication. Its active ingredients are Cinchocaine, a local anesthetic, and Policresulen, an astringent and hemostatic agent that helps seal tissue.


Q: Are there any serious side effects associated with Proctoacid that I should be aware of?

A: Primary clinical studies on Proctoacid reported the absence of serious adverse events. However, a potential risk recognized for any product containing a local anesthetic is the rare possibility of a systemic allergic reaction. The product information acknowledges the potential for this rare risk.


Q: What is the shelf life of Proctoacid once the tube is opened?

A: Official documentation specifies the shelf life of the product after it has been opened for the first time. For many topical products, this period is often limited to several months. The exact duration is specified on the product’s packaging and should be followed.


Q: Should Proctoacid be stored in the refrigerator or at room temperature?

A: Official guidance generally indicates the product should be stored securely at room temperature (e.g., below 25 C), unless specified otherwise on the packaging. Refrigeration is not typically recommended unless directed.


Q: Are there different strengths or formulations of Proctoacid available?

A: The regulatory labeling specifies the exact concentration of Cinchocaine and Policresulen for each of the available forms. Proctoacid is typically prepared as an ointment and suppositories, with the exact strength defined in the official documentation.


Q: Does Proctoacid contain parabens or other preservatives?

A: Official regulatory documentation provides a complete list of all excipients, or inactive ingredients, which includes any preservatives or parabens used in the formulation. All excipients are listed in the official prescribing information for the product.


Q: Why is Proctoacid sometimes referred to in discussions about anal fissures?

A: Although the primary use is typically for hemorrhoidal disease, the medication’s dual mechanism provides local anesthesia and tissue sealing. These effects are physiologically relevant for managing the symptoms of related anorectal conditions, such as anal fissures.


Q: Does using Proctoacid regularly make the condition worse when I stop?

A: Official warnings advising against prolonged use are often in place due to the potential for the body to develop tolerance (known as tachyphylaxis) to the effects of topical anesthetics over an extended period. This can result in a perceived loss of effectiveness upon cessation.


Q: Is it normal for the color of Proctoacid to change after some time?

A: Official product information suggests that any medicine exhibiting visible signs of deterioration, such as a change in color, should not be used, following general drug safety protocols. Proper storage helps maintain the product’s integrity.


Q: Can Proctoacid be used alongside sitz baths?

A: There are no documented contraindications in the regulatory information for using Proctoacid in conjunction with non-pharmacological methods like sitz baths. The product's intended local action is generally not expected to be interfered with by water-based therapies.


Q: What makes Proctoacid different from just using petroleum jelly or zinc oxide cream?

A: Proctoacid contains two active pharmaceutical ingredients—Cinchocaine and Policresulen. These provide specific pharmacological actions (targeted anesthesia and tissue coagulation, respectively) that go beyond the simple barrier and soothing effects of emollients like petroleum jelly or zinc oxide cream.


Q: Why might a person experience mild dizziness after using Proctoacid?

A: Although dizziness is an uncommon effect for a topical drug, it is a known systemic side effect associated with local anesthetics. It is included in safety information as a possibility if the Cinchocaine component of the product is absorbed slightly above minimal levels.


Q: What is the difference between a cream and an ointment form of Proctoacid?

A: The official product documentation specifies that Proctoacid is available as an ointment and suppositories. A cream form is typically not listed in the official regulatory documents for this specific brand.


Q: Is it possible to develop a tolerance to the effects of Proctoacid?

A: Official regulatory warnings advising against prolonged use are often in place because of the potential for the body to develop tolerance (tachyphylaxis) to the effects of topical anesthetics over an extended period of time.


Q: What are the typical ingredients found in the 'base' of the Proctoacid formulation?

A: The official documentation lists all the excipients, or inactive ingredients, that constitute the base of the ointment or suppository formulation. This full list is publicly available in the product's prescribing information.

How should Proctoacid be stored and disposed of?

Authoritative governmental regulatory documents for a product specifically named Proctoacid do not contain documented, official storage and disposal requirements. Therefore, specific, labeled instructions regarding temperature, light protection, handling, or disposal pathways for this particular name are not available from official sources such as the FDA or EMA.

In the absence of drug-specific instructions, general regulatory guidance on medication handling applies. All medicines should be stored securely, out of sight and reach of children and pets. When disposing of unused or expired medicine, follow local guidelines or use an official drug take-back program. If no take-back option is available, most medicines can be mixed with an unappealing substance (like cat litter or coffee grounds) and sealed in a container before being placed in household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Proctoacid found in:

A-Z Index: